IGC Pharma Receives Notice of Allowance for Patent on Seizures
POTOMAC, Md., June 06, 2023--(BUSINESS WIRE)--IGC Pharma, Inc. (NYSE American: IGC) ("IGC" or the "Company"), today announced that it has received a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (IGC-501). The formulation also received an intent to grant from the European Patent Office. With these awards, and a previous one, the formulation for treating seizures is protected in the U.S., Canada, and certain European countries.
IGC provided animal data, with dogs, on the reduction in the number of seizures by using a combination of cannabidiol (CBD) and phenobarbital versus either alone. The Company intends to pursue the combination in further trials with a view towards monetizing the formulation as soon as practical. One potential market is dogs in America. There are about 63.4 million dogs in the U.S. and approximately, 1 in 20 may experience a seizure in their lifetime. A seizure is a sudden surge in the electrical activity of the brain that causes twitching, shaking, tremors, convulsions, and (or) spasms. Seizures can last a few seconds to a few minutes. The Company’s intellectual property includes over 40 filed patent applications in various countries, including the U.S.
About IGC Pharma, Inc.
IGC Pharma (dba IGC) develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps ("dysmenorrhea"), premenstrual syndrome ("PMS") and chronic pain. IGC has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol ("THC") based formulation that is currently in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). IGC also markets a wellness brand, Holief™, that targets women experiencing premenstrual syndrome and menstrual cramps. For more information visit https://igcpharma.com/
Forward-looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC’s U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 23, 2022, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230606005269/en/
Contacts
IMS Investor Relations
Walter Frank
igc@imsinvestorrelations.com
(203) 972-9200
